PLANETRA

Efficacy
Safety Profile

Inflectra^®/CT-P13* (infliximab) is therapeutically comparable to Remicade^® in RA^18,20,35.

ACR20 response in adult patients with active RA^18,20,35

All efficacy endpoints were comparable during long-term treatment in the maintenance and switch groups²⁰

A comparable safety profile to Remicade^® was demonstrated by Inflectra^®/CT-P13* (infliximab) which was maintained long term in RA^18,20,35.

Treatment-emergent adverse events (TEAE)^18,20,37

Prescribing Information

Inflectra^® Summary of Product Characteristics | Legal Category: POM Basic NHS Price: 1 vial £377.66

*CT-P13 is marketed under different brand names including INFLECTRA® and REMSIMA®.
†Remicade® is a registered trademark of MSD.
ҩ Therapeutic equivalence of clinical response according to ACR20 criteria was concluded if the 95% CI for the treatment difference was within ± 15%¹⁸.
ɣ Primary endpoint.
# ITT population

RA, Rheumatoid Arthritis; CI, Confidence interval; ITT, Intention-to-treat; PP, Per-protocol.

PP-IFA-GBR-0288. December 2018